Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
33.40
+1.84 (5.83%)
At close: Jul 17, 2026, 4:00 PM EDT
32.74
-0.66 (-1.98%)
After-hours: Jul 17, 2026, 6:26 PM EDT
Septerna Employees
Septerna had 130 employees as of December 31, 2025. The number of employees increased by 55 or 73.33% compared to the previous year.
Employees
130
Change (1Y)
55
Growth (1Y)
73.33%
Revenue / Employee
$555,808
Profits / Employee
-$277,231
Market Cap
1.51B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 55 | 73.33% |
| Dec 31, 2024 | 75 | - | - |
| Sep 30, 2024 | 73 | - | - |
| Jun 30, 2024 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immatics | 678 |
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Maze Therapeutics | 141 |
| Absci | 140 |
| MoonLake Immunotherapeutics | 130 |
| Inhibrx Biosciences | 110 |
SEPN News
- 17 days ago - Septerna price target raised to $43 from $35 at Truist - TheFly
- 17 days ago - Septerna price target lowered to $45 from $52 at Guggenheim - TheFly
- 22 days ago - Septerna Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Septerna initiated with a Buy at Guggenheim - TheFly
- 5 weeks ago - Septerna to present preclinical characterization of SEP-479 - TheFly
- 5 weeks ago - Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting - Business Wire
- 5 weeks ago - Septerna price target raised to $53 from $47 at Raymond James - TheFly
- 7 weeks ago - 3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026 - TipRanks